CANNABIS BUZZ Pure play marijuana stocks are scarce. Most companies in the marijuana industry trade over the counter (OTC), where solid information regarding operations and financials is




Cannabis Stock 

CANNABIS BUZZ Pure play marijuana stocks are scarce. Most companies in the marijuana industry trade over the counter (OTC), where solid information regarding operations and financials is difficult to retrieve. Exceptions extend to issues such as GW Pharmaceuticals plc (NASDAQ: GWPH), a British biopharmaceutical company that developed two cannabis-based drugs licensed for use outside the United States. Sativex is used to treat muscular contractions in multiple sclerosis patients, and Epidiolex targets epileptic seizures in children. Both drugs have entered Phase 3 clinical stage trials in the United States. GWPH has a $2 billion market cap and had returned 23% year to date (YTD) as of Aug. 15, 2016.

Political and legal obstacles remain the highest hurdles for the marijuana industry in 2016. Four states, Oregon, Washington, Alaska and Colorado, have legalized recreational marijuana, and 25 states plus the District of Columbia have approved cannabis for medicinal purposes. The plant is categorized at the federal level as a Schedule 1 drug, possessing the highest risk for psychological and physical dependence, and more curiously, having no acceptable medical use.

BUZ INVESTORS PRESS RELEASE Debenture Offering Aurora Cannabis Inc. (the "Company" or "Aurora") (TSXV: ACB) (OTCQX: ACBFF) (
CANNABIS BUZZ PRESS RELEASES

Actions Versus Words: Aurora CEO’s Actions Reveal That Aurora Stock is Inflated; Insiders Sell $17 Million in Stock During Their Hostile Take-over Bid for CanniMed and During a Financing

Actions Versus Words: Aurora CEO’s Actions Reveal That Aurora Stock is Inflated; Insiders Sell $17 Million in Stock During Their Hostile Take-over Bid for CanniMed and During a Financing Despite trying to convince CanniMed shareholders to take Aurora’s shares in their opportunistic and coercive hostile bid, Aurora insiders’ cash out evidences their belief that Aurora’s […]

BUZ INVESTORS PRESS RELEASE Comprehensive Amendment Agreements Tauriga Sciences Inc. ( OTC PINK : (TAUG ) (“Tauriga” or “the Company”),
CANNABIS BUZZ PRESS RELEASES

Tauriga Sciences, Inc. Announces the Relocation of its Corporate Headquarters to Midtown Manhattan

Tauriga Sciences, Inc. Announces the Relocation of its Corporate Headquarters to Midtown Manhattan NEW YORK, NY–(Marketwired – Nov 29, 2017) – Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”) today announced that it has decided to move its corporate headquarters from Danbury, Connecticut to Midtown Manhattan in New York City. The effective date of this […]

BUZ INVESTORS Definitive Agreement Tetra Bio-Pharma Inc. (“Tetra” orCN)announced today
CANNABIS BUZZ PRESS RELEASES

Tetra Bio-Pharma accelerates submission of New Drug Application to FDA & Expects to Commercialize Dronabinol XL Tablet

Tetra Bio-Pharma accelerates submission of New Drug Application to FDA & Expects to Commercialize Dronabinol XL Tablet Ahead of Schedule(1) in the US   OTTAWA, ONTARIO–(Marketwired – Nov. 28, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), a global leader in cannabinoid-based drug development, today announced that it is partnering with […]

BUZ INVESTORS Emerald Announces Inclusion - Emerald Health Therapeutics Inc. (TSXV:EMH) ("Emerald" or the "Company") is pleased to announce its inclusion in the Horizon Medical Marijuana Life Sciences ETF
CANNABIS BUZZ PRESS RELEASES

Emerald Health Therapeutics Announces Positive Health Canada Review of License Application for Prominent Fourth Facility

Emerald Health Therapeutics Announces Positive Health Canada Review of License Application for Prominent Fourth Facility   Construction of first 75,000 square feet of new greenhouse targeted for completion in March 2018; next expansion phase to over 500,000 square feet to be completed by end 2018 VICTORIA, BC – (November 28, 2017) – Emerald Health Therapeutics […]

US Patent Office Acknowledges Provisional Patent Application for Use of Specific Cannabis Strain to Enhance Opioid Analgesia Filed by Veritas’ Research Arm Cannevert
CANNABIS BUZZ PRESS RELEASES

US Patent Office Acknowledges Provisional Patent Application for Use of Specific Cannabis Strain to Enhance Opioid Analgesia Filed by Veritas’ Research Arm Cannevert

US Patent Office Acknowledges Provisional Patent Application for Use of Specific Cannabis Strain to Enhance Opioid Analgesia Filed by Veritas’ Research Arm Cannevert November 28, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), (“Veritas” or the “Company”) announces its research arm, Cannevert Therapeutics Ltd. (“CTL”) filed a provisional patent […]